Clinical Trials Related to Triple Negative Breast Cancer

Related studies linked through entity extraction aliases.

Abraxane With or Without Tigatuzumab in Patients With Metastatic, Triple Negative Breast Cancer

Status: COMPLETED
Phase: PHASE2

Study to Identify Molecular Mechanisms of Clinical Resistance to Chemotherapy in Triple Negative Breast Cancer Patients

Status: COMPLETED
Phase: N/A

Comparison Study of Neoadjuvant Paclitaxel Plus Carboplatin/Epirubicin Treatment in Triple-negative Breast Cancer

Status: UNKNOWN
Phase: PHASE2

Adjuvant Platinum and Taxane in Triple-negative Breast Cancer (PATTERN)

Status: COMPLETED
Phase: PHASE3

Triple Negative Breast Cancer Biomarker Study

Status: COMPLETED
Phase: N/A

Study of Temsirolimus, Erlotinib and Cisplatin in Solid Tumors

Status: COMPLETED
Phase: PHASE1

A Study of NK012 in Patients With Advanced, Metastatic Triple Negative Breast Cancer

Status: COMPLETED
Phase: PHASE2

A Phase 2 Study of Standard Chemotherapy Plus BSI-201 (a PARP Inhibitor) in the Neoadjuvant Treatment of Triple Negative Breast Cancer

Status: COMPLETED
Phase: PHASE2

Phase I/II Study of AZD2281 Given in Combination With Paclitaxel in Metastatic Triple Negative Breast Cancer

Status: COMPLETED
Phase: PHASE1